12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MDT-637: Phase I data

The double-blind, placebo-controlled, U.S. Phase I Study MDT-637-CP-103 trial in 10 patients with mild to moderate persistent asthma showed that single ascending-doses of MDT-637 up to 132 µg thrice daily were well tolerated with no significant adverse events or clinically significant changes in lung function reported. No cohorts...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >